Global specialty ingredients solution provider Barentz International recently announced the acquisition of Anshul Life Sciences in India, a specialty chemicals distributor that caters to regulated pharmaceuticals, food & nutraceuticals, and personal care markets.
With this acquisition, Barentz establishes a life science distribution platform in India. It is expected to open a realm of strategic opportunities for growth across the country and the broader Asia Pacific region. Both companies are committed to ensuring a seamless transition and maintaining the highest standards of value-added services. Nagarajan Kailasam (CEO, Anshul Life Sciences) and the current team of Anshul Life Sciences will continue to manage the day-to-day business operations.
“We are extremely excited to welcome Anshul Life Sciences to the Barentz Group,” commented Marc Duchene, CEO APAC. “The acquisition underpins our ambitions to further grow in India, one of our key strategic markets, and the Asia Pacific region in general. The acquisition benefits our customers and principals by providing access to a broader portfolio of high-quality pharmaceuticals excipients and products and a deeper pool of expertise. We are delighted that Mr. Nagarajan will continue to lead the business. Together, we aim to enhance our offering and better serve the needs of the dynamic Indian market and beyond.”
“Barentz aligns strongly with the entrepreneurial spirit and ethical standards of Anshul Life Science’s founding partners,” added Nagarajan Kailasam, CEO of Anshul Life Sciences. “We are excited to join the Barentz family and start our collaboration to capture the enormous potential of the Indian market by offering even more comprehensive solutions to our customers and principals in the Indian market and beyond. We are looking forward to the future and the growing international reach that this strategic move will bring to Anshul Life Sciences.”
Source: chemanager-online.com
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
